AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. IVVD
  4. [Form 4] Invivyd, Inc. Insider Trading Activity

[Form 4] Invivyd, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Timothy Edward Lee, Chief Commercial Officer of Invivyd, Inc. (IVVD), reported equity activity arising from an RSU grant and subsequent sell-to-cover transactions executed under a Rule 10b5-1 plan.

On 08/15/2025 Mr. Lee was granted 99,000 RSUs (each converting to one share) that vest over 18 months with one-third vesting every six months. After accounting for the RSUs and existing holdings (including 10,000 shares from the company ESPP), the reported post-transaction beneficial ownership is 201,000 shares. To satisfy tax withholding upon RSU vesting, Mr. Lee sold 20,013 shares on 08/18/2025 at a weighted average price of $0.6502 and 29,643 shares on 08/19/2025 at a weighted average price of $0.5666. The sales were non-discretionary sell-to-cover transactions pursuant to a 10b5-1 plan adopted 02/20/2025.

Timothy Edward Lee, Chief Commercial Officer di Invivyd, Inc. (IVVD), ha dichiarato operazioni su titoli derivanti da una concessione di RSU e dalle successive vendite per copertura delle imposte eseguite nell'ambito di un piano Rule 10b5-1.

In data 15/08/2025 il Sig. Lee ha ricevuto 99.000 RSU (ognuna convertibile in una azione) che maturano in 18 mesi con un terzo che matura ogni sei mesi. Tenendo conto delle RSU e delle partecipazioni gi脿 possedute (inclusi 10.000 azioni provenienti dall'ESPP aziendale), la propriet脿 beneficiaria riportata dopo le operazioni 猫 di 201.000 azioni. Per far fronte alle ritenute fiscali alla maturazione delle RSU, il Sig. Lee ha venduto 20.013 azioni il 18/08/2025 a un prezzo medio ponderato di $0,6502 e 29.643 azioni il 19/08/2025 a un prezzo medio ponderato di $0,5666. Le vendite sono state operazioni non discrezionali di tipo sell-to-cover ai sensi di un piano 10b5-1 adottato il 20/02/2025.

Timothy Edward Lee, Chief Commercial Officer de Invivyd, Inc. (IVVD), inform贸 actividad patrimonial derivada de una concesi贸n de RSU y posteriores operaciones de venta para cubrir impuestos ejecutadas bajo un plan Rule 10b5-1.

El 15/08/2025 el Sr. Lee recibi贸 99.000 RSU (cada una convertida en una acci贸n) que se consolidan en 18 meses con un tercio consolid谩ndose cada seis meses. Tras contabilizar las RSU y las participaciones existentes (incluidas 10.000 acciones del ESPP de la compa帽铆a), la propiedad beneficiaria informada tras las transacciones es de 201.000 acciones. Para satisfacer la retenci贸n fiscal al consolidarse las RSU, el Sr. Lee vendi贸 20.013 acciones el 18/08/2025 a un precio medio ponderado de $0,6502 y 29.643 acciones el 19/08/2025 a un precio medio ponderado de $0,5666. Las ventas fueron operaciones no discrecionales de tipo sell-to-cover conforme a un plan 10b5-1 adoptado el 20/02/2025.

Timothy Edward Lee, Invivyd, Inc. (IVVD)鞚� 斓滉碃 靸侅梾 毂呾瀯鞛�(Chief Commercial Officer)電� RSU 攵�鞐� 氚� Rule 10b5-1 頂岆灉鞐� 霐半澕 鞚错枆霅� 靹戈笀 雮╇秬 氇╈爜鞚� 毵る弰(靺�-韴�-旎る矂) 瓯半灅搿� 鞚疙暅 欤检嫕 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟.

2025-08-15鞚检棎 Lee 鞌姅 99,000 RSU(臧侁皝 1欤茧 鞝勴櫂)毳� 攵�鞐皼鞎橃溂氅�, 鞚措摛鞚� 18臧滌洈鞐� 瓯胳硱 旆摑霅橂┌ 6臧滌洈毵堧嫟 1/3鞌� 旆摑霅╇媹雼�. RSU鞕� 旮办〈 氤挫湢 欤检嫕(須岇偓 ESPP搿滊秬韯办潣 10,000欤� 韽暔)鞚� 氚橃榿頃� 瓯半灅 頉� 氤搓碃霅� 鞁れ唽鞙� 歆�攵勳潃 201,000欤�鞛呺媹雼�. RSU 旆摑 鞁� 鞗愳矞歆曥垬 靹戈笀鞚� 於╇嫻頃橁赴 鞙勴暣 Lee 鞌姅 2025-08-18鞐� 臧�欷戫弶攴� 臧�瓴� $0.6502搿� 20,013欤�毳�, 2025-08-19鞐� 臧�欷戫弶攴� 臧�瓴� $0.5666搿� 29,643欤�毳� 毵る弰頄堨姷雼堧嫟. 頃措嫻 毵る弰電� 2025-02-20鞐� 毂勴儩霅� 10b5-1 頂岆灉鞐� 霐半ジ 牍勳灛霟夓爜 靺�-韴�-旎る矂 瓯半灅鞓�鞀惦媹雼�.

Timothy Edward Lee, Chief Commercial Officer d'Invivyd, Inc. (IVVD), a d茅clar茅 des op茅rations sur titres r茅sultant d'une attribution de RSU et des ventes ult茅rieures pour couvrir l'imp么t, effectu茅es dans le cadre d'un plan Rule 10b5-1.

Le 15/08/2025 M. Lee a re莽u 99 000 RSU (chacune convertible en une action) qui acqui猫rent des droits sur 18 mois, un tiers acqu茅rant tous les six mois. En tenant compte des RSU et des participations existantes (y compris 10 000 actions issues du plan ESPP de la soci茅t茅), la d茅tention b茅n茅ficiaire d茅clar茅e apr猫s les op茅rations est de 201 000 actions. Pour satisfaire les retenues fiscales 脿 l'acquisition des RSU, M. Lee a vendu 20 013 actions le 18/08/2025 au prix moyen pond茅r茅 de $0,6502 et 29 643 actions le 19/08/2025 au prix moyen pond茅r茅 de $0,5666. Les ventes 茅taient des op茅rations non discr茅tionnaires de type sell-to-cover conform茅ment 脿 un plan 10b5-1 adopt茅 le 20/02/2025.

Timothy Edward Lee, Chief Commercial Officer von Invivyd, Inc. (IVVD), meldete Aktienbewegungen im Zusammenhang mit einer Zuteilung von RSU und anschlie脽enden Sell-to-Cover-Transaktionen, die gem盲脽 einem Rule-10b5-1-Plan ausgef眉hrt wurden.

Am 15.08.2025 wurden Herrn Lee 99.000 RSU gew盲hrt (jeweils in eine Aktie umwandelbar), die 眉ber 18 Monate mit einem Drittel alle sechs Monate vesten. Unter Ber眉cksichtigung der RSU und der bereits gehaltenen Best盲nde (einschlie脽lich 10.000 Aktien aus dem unternehmenseigenen ESPP) betr盲gt das nach den Transaktionen gemeldete wirtschaftliche Eigentum 201.000 Aktien. Zur Begleichung der Steuerabz眉ge bei Vesting der RSU verkaufte Herr Lee am 18.08.2025 20.013 Aktien zu einem durchschnittlichen gewichteten Preis von $0,6502 und am 19.08.2025 29.643 Aktien zu einem durchschnittlichen gewichteten Preis von $0,5666. Die Verk盲ufe waren nicht-discretion盲re Sell-to-Cover-Transaktionen gem盲脽 einem am 20.02.2025 angenommenen 10b5-1-Plan.

Positive
  • Transparent disclosure of RSU grant size, vesting schedule, and 10b5-1 plan adoption date
  • Sell-to-cover sales were executed under a pre-established 10b5-1 plan, indicating non-discretionary tax withholding activity
  • Reporting includes weighted-average prices and commitment to provide per-trade details on request
Negative
  • None.

Insights

TL;DR: Routine RSU vesting with sell-to-cover tax sales limits dilution and indicates no discretionary insider selling.

The filing shows an RSU grant of 99,000 units vesting over 18 months and contemporaneous sell-to-cover disposals to satisfy withholding. The use of a 10b5-1 plan (adopted 02/20/2025) and disclosure of weighted-average sale prices provide procedural transparency. The net effect increased reported beneficial ownership to 201,000 shares, so these transactions are largely administrative rather than opportunistic cashing out.

TL;DR: Disclosure is compliant and detailed; sales were for tax withholding under a pre-established plan.

The Form 4 discloses material elements required for compliance: grant size, vesting schedule, adoption date of the 10b5-1 plan, and weighted-average sale price ranges with an offer to provide per-trade breakdowns on request. This level of disclosure supports good governance practices for executive equity awards and tax-related withholding sales.

Timothy Edward Lee, Chief Commercial Officer di Invivyd, Inc. (IVVD), ha dichiarato operazioni su titoli derivanti da una concessione di RSU e dalle successive vendite per copertura delle imposte eseguite nell'ambito di un piano Rule 10b5-1.

In data 15/08/2025 il Sig. Lee ha ricevuto 99.000 RSU (ognuna convertibile in una azione) che maturano in 18 mesi con un terzo che matura ogni sei mesi. Tenendo conto delle RSU e delle partecipazioni gi脿 possedute (inclusi 10.000 azioni provenienti dall'ESPP aziendale), la propriet脿 beneficiaria riportata dopo le operazioni 猫 di 201.000 azioni. Per far fronte alle ritenute fiscali alla maturazione delle RSU, il Sig. Lee ha venduto 20.013 azioni il 18/08/2025 a un prezzo medio ponderato di $0,6502 e 29.643 azioni il 19/08/2025 a un prezzo medio ponderato di $0,5666. Le vendite sono state operazioni non discrezionali di tipo sell-to-cover ai sensi di un piano 10b5-1 adottato il 20/02/2025.

Timothy Edward Lee, Chief Commercial Officer de Invivyd, Inc. (IVVD), inform贸 actividad patrimonial derivada de una concesi贸n de RSU y posteriores operaciones de venta para cubrir impuestos ejecutadas bajo un plan Rule 10b5-1.

El 15/08/2025 el Sr. Lee recibi贸 99.000 RSU (cada una convertida en una acci贸n) que se consolidan en 18 meses con un tercio consolid谩ndose cada seis meses. Tras contabilizar las RSU y las participaciones existentes (incluidas 10.000 acciones del ESPP de la compa帽铆a), la propiedad beneficiaria informada tras las transacciones es de 201.000 acciones. Para satisfacer la retenci贸n fiscal al consolidarse las RSU, el Sr. Lee vendi贸 20.013 acciones el 18/08/2025 a un precio medio ponderado de $0,6502 y 29.643 acciones el 19/08/2025 a un precio medio ponderado de $0,5666. Las ventas fueron operaciones no discrecionales de tipo sell-to-cover conforme a un plan 10b5-1 adoptado el 20/02/2025.

Timothy Edward Lee, Invivyd, Inc. (IVVD)鞚� 斓滉碃 靸侅梾 毂呾瀯鞛�(Chief Commercial Officer)電� RSU 攵�鞐� 氚� Rule 10b5-1 頂岆灉鞐� 霐半澕 鞚错枆霅� 靹戈笀 雮╇秬 氇╈爜鞚� 毵る弰(靺�-韴�-旎る矂) 瓯半灅搿� 鞚疙暅 欤检嫕 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟.

2025-08-15鞚检棎 Lee 鞌姅 99,000 RSU(臧侁皝 1欤茧 鞝勴櫂)毳� 攵�鞐皼鞎橃溂氅�, 鞚措摛鞚� 18臧滌洈鞐� 瓯胳硱 旆摑霅橂┌ 6臧滌洈毵堧嫟 1/3鞌� 旆摑霅╇媹雼�. RSU鞕� 旮办〈 氤挫湢 欤检嫕(須岇偓 ESPP搿滊秬韯办潣 10,000欤� 韽暔)鞚� 氚橃榿頃� 瓯半灅 頉� 氤搓碃霅� 鞁れ唽鞙� 歆�攵勳潃 201,000欤�鞛呺媹雼�. RSU 旆摑 鞁� 鞗愳矞歆曥垬 靹戈笀鞚� 於╇嫻頃橁赴 鞙勴暣 Lee 鞌姅 2025-08-18鞐� 臧�欷戫弶攴� 臧�瓴� $0.6502搿� 20,013欤�毳�, 2025-08-19鞐� 臧�欷戫弶攴� 臧�瓴� $0.5666搿� 29,643欤�毳� 毵る弰頄堨姷雼堧嫟. 頃措嫻 毵る弰電� 2025-02-20鞐� 毂勴儩霅� 10b5-1 頂岆灉鞐� 霐半ジ 牍勳灛霟夓爜 靺�-韴�-旎る矂 瓯半灅鞓�鞀惦媹雼�.

Timothy Edward Lee, Chief Commercial Officer d'Invivyd, Inc. (IVVD), a d茅clar茅 des op茅rations sur titres r茅sultant d'une attribution de RSU et des ventes ult茅rieures pour couvrir l'imp么t, effectu茅es dans le cadre d'un plan Rule 10b5-1.

Le 15/08/2025 M. Lee a re莽u 99 000 RSU (chacune convertible en une action) qui acqui猫rent des droits sur 18 mois, un tiers acqu茅rant tous les six mois. En tenant compte des RSU et des participations existantes (y compris 10 000 actions issues du plan ESPP de la soci茅t茅), la d茅tention b茅n茅ficiaire d茅clar茅e apr猫s les op茅rations est de 201 000 actions. Pour satisfaire les retenues fiscales 脿 l'acquisition des RSU, M. Lee a vendu 20 013 actions le 18/08/2025 au prix moyen pond茅r茅 de $0,6502 et 29 643 actions le 19/08/2025 au prix moyen pond茅r茅 de $0,5666. Les ventes 茅taient des op茅rations non discr茅tionnaires de type sell-to-cover conform茅ment 脿 un plan 10b5-1 adopt茅 le 20/02/2025.

Timothy Edward Lee, Chief Commercial Officer von Invivyd, Inc. (IVVD), meldete Aktienbewegungen im Zusammenhang mit einer Zuteilung von RSU und anschlie脽enden Sell-to-Cover-Transaktionen, die gem盲脽 einem Rule-10b5-1-Plan ausgef眉hrt wurden.

Am 15.08.2025 wurden Herrn Lee 99.000 RSU gew盲hrt (jeweils in eine Aktie umwandelbar), die 眉ber 18 Monate mit einem Drittel alle sechs Monate vesten. Unter Ber眉cksichtigung der RSU und der bereits gehaltenen Best盲nde (einschlie脽lich 10.000 Aktien aus dem unternehmenseigenen ESPP) betr盲gt das nach den Transaktionen gemeldete wirtschaftliche Eigentum 201.000 Aktien. Zur Begleichung der Steuerabz眉ge bei Vesting der RSU verkaufte Herr Lee am 18.08.2025 20.013 Aktien zu einem durchschnittlichen gewichteten Preis von $0,6502 und am 19.08.2025 29.643 Aktien zu einem durchschnittlichen gewichteten Preis von $0,5666. Die Verk盲ufe waren nicht-discretion盲re Sell-to-Cover-Transaktionen gem盲脽 einem am 20.02.2025 angenommenen 10b5-1-Plan.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lee Timothy Edward
(Last) (First) (Middle)
C/O INVIVYD, INC.
1601 TRAPELO ROAD, SUITE 178
(Street)
WALTHAM MA 02451
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Invivyd, Inc. [ IVVD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Commercial Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/15/2025 M 99,000 A (1) 109,000(2) D
Common Stock 08/18/2025 S 20,013(3) D $0.6502(4) 88,987 D
Common Stock 08/19/2025 S 29,643(3) D $0.5666(5) 59,344 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 08/15/2025 M 99,000 (6) (6) Common Stock 99,000 $0.00 201,000 D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Invivyd, Inc. (the "Company").
2. The reported ownership includes 10,000 shares of common stock acquired through the Company's Employee Stock Purchase Program.
3. The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.
4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.5801 to $0.7134, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.5524 to $0.6040, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
6. This RSU award vests over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, subject to the Reporting Person's continuous service as of each vesting date.
Remarks:
Exhibit 24.1: Power of Attorney
/s/ Jill Andersen attorney-in-fact for Timothy Edward Lee 08/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

Who filed the Form 4 for IVVD and what is their role?

The Form 4 was filed for Timothy Edward Lee, who is the company's Chief Commercial Officer.

How many RSUs were granted to the reporting person on 08/15/2025?

The reporting person was granted 99,000 restricted stock units (RSUs) on 08/15/2025.

Why were shares sold on 08/18 and 08/19/2025 and under what plan?

The shares were sold to satisfy tax withholding obligations upon RSU vesting via non-discretionary sell-to-cover transactions under a Rule 10b5-1 plan adopted 02/20/2025.

What were the weighted-average prices for the sales reported?

The weighted-average price for the 08/18/2025 sales was $0.6502 and for 08/19/2025 sales was $0.5666.

What is the reporting person鈥檚 beneficial ownership after these transactions?

The reported beneficial ownership following the transactions is 201,000 shares, which includes 10,000 shares acquired through the company ESPP.
Stock IVVD logo
Invivyd

NASDAQ:IVVD

IVVD Rankings

#5006 Ranked by Market Cap
N/A Ranked by Dividends
#1 Top Loser

IVVD Latest News

Aug 20, 2025
Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants
Aug 20, 2025
Invivyd Announces Proposed Public Offering of Common Stock
Aug 18, 2025
Invivyd Announces Continued Neutralizing Activity of PEMGARDA庐 (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (鈥淪tratus鈥�)
Aug 14, 2025
Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Aug 14, 2025
Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

IVVD Latest SEC Filings

Aug 20, 2025
[424B5] Invivyd, Inc. Prospectus Supplement (Debt Securities)
Aug 19, 2025
[Form 4] Invivyd, Inc. Insider Trading Activity
Aug 19, 2025
[Form 4] Invivyd, Inc. Insider Trading Activity
Aug 19, 2025
[Form 4] Invivyd, Inc. Insider Trading Activity
Aug 19, 2025
[Form 4] Invivyd, Inc. Insider Trading Activity

IVVD Stock Data

69.71M
69.63M
41.12%
57.5%
2.77%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
WALTHAM